{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:05:48Z","timestamp":1779444348145,"version":"3.53.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00467-025-06985-x","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:45:34Z","timestamp":1760957134000},"page":"1967-1981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kidney disease and transplantation in childhood cancer survivors"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7593-6151","authenticated-orcid":false,"given":"Abigail S.","family":"Kane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1186-669X","authenticated-orcid":false,"given":"Wendy C.","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"6985_CR1","unstructured":"American Cancer Society (2024) ACS Cancer Facts and Figures 2024. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2024\/2024-cancer-facts-and-figures-acs.pdf. Accessed 09 Feb 2025"},{"key":"6985_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(17)30186-9","volume":"18","author":"E Steliarova-Foucher","year":"2017","unstructured":"Steliarova-Foucher E, Colombet M, Ries LAG et al (2017) International incidence of childhood cancer, 2001\u201310: a population-based registry study. Lancet Oncol 18:719\u2013731. https:\/\/doi.org\/10.1016\/S1470-2045(17)30186-9","journal-title":"Lancet Oncol"},{"key":"6985_CR3","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(22)02471-0","volume":"401","author":"SB Dixon","year":"2023","unstructured":"Dixon SB, Liu Q, Chow EJ et al (2023) Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the childhood cancer survivor study cohort. Lancet 401:1447\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(22)02471-0","journal-title":"Lancet"},{"key":"6985_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104147","volume":"192","author":"OA Asogwa","year":"2023","unstructured":"Asogwa OA, Quansah DY, Boakye D et al (2023) Prevalence, patterns, and determinants of multimorbidity among childhood and adult cancer survivors: a systematic review. Crit Rev Oncol Hematol 192:104147","journal-title":"Crit Rev Oncol Hematol"},{"key":"6985_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejca.2021.06.050","volume":"155","author":"B Dieffenbach","year":"2021","unstructured":"Dieffenbach B, Liu Q, Murphy AJ et al (2021) Late-onset kidney failure in survivors of childhood cancer: a report from the childhood cancer survivor study. Eur J Cancer 155:216\u2013226. https:\/\/doi.org\/10.1016\/j.ejca.2021.06.050","journal-title":"Eur J Cancer"},{"key":"6985_CR6","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1053\/j.ackd.2021.09.001","volume":"28","author":"BR Stotter","year":"2021","unstructured":"Stotter BR, Chan C, Chanchlani R (2021) Late kidney effects of childhood cancer and cancer therapies. Adv Chronic Kidney Dis 28:490-501.e1. https:\/\/doi.org\/10.1053\/j.ackd.2021.09.001","journal-title":"Adv Chronic Kidney Dis"},{"key":"6985_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/s41390-022-02015-w","volume":"92","author":"AAS Mahmoud","year":"2022","unstructured":"Mahmoud AAS, Elsalam HBA, El-Deeb SM et al (2022) Evaluation of kidney dysfunction in childhood cancer survivors. Pediatr Res 92:1689\u20131694. https:\/\/doi.org\/10.1038\/s41390-022-02015-w","journal-title":"Pediatr Res"},{"key":"6985_CR8","doi-asserted-by":"publisher","first-page":"CD008944","DOI":"10.1002\/14651858.CD008944.pub3","volume":"3","author":"EC Kooijmans","year":"2019","unstructured":"Kooijmans EC, B\u00f6kenkamp A, Tjahjadi NS et al (2019) Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 3:CD008944. https:\/\/doi.org\/10.1002\/14651858.CD008944.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"6985_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/967826","volume":"2014","author":"A Ozkok","year":"2014","unstructured":"Ozkok A, Edelstein CL (2014) Pathophysiology of Cisplatin-induced acute kidney injury. Biomed Res Int 2014:1\u201317. https:\/\/doi.org\/10.1155\/2014\/967826","journal-title":"Biomed Res Int"},{"key":"6985_CR10","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00204-012-0821-7","volume":"86","author":"NAG dos Santos","year":"2012","unstructured":"dos Santos NAG, Carvalho Rodrigues MA, Martins NM, dos Santos AC (2012) Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 86:1233\u20131250. https:\/\/doi.org\/10.1007\/s00204-012-0821-7","journal-title":"Arch Toxicol"},{"issue":"12","key":"6985_CR11","doi-asserted-by":"publisher","first-page":"9681","DOI":"10.3390\/curroncol29120760","volume":"29","author":"J Ha\u0142ka","year":"2022","unstructured":"Ha\u0142ka J, Spaleniak S, Kade G et al (2022) The nephrotoxicity of drugs used in causal oncological therapies. Curr Oncol 29:9681\u20139694. https:\/\/doi.org\/10.3390\/curroncol29120760","journal-title":"Curr Oncol"},{"key":"6985_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00467-017-3662-z","volume":"33","author":"R Skinner","year":"2018","unstructured":"Skinner R (2018) Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. Pediatr Nephrol 33:215\u2013225. https:\/\/doi.org\/10.1007\/s00467-017-3662-z","journal-title":"Pediatr Nephrol"},{"key":"6985_CR13","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v70i2.1641","volume":"70","author":"K Almanric","year":"2017","unstructured":"Almanric K, Marceau N, Cantin A, Bertin \u00c9 (2017) Risk factors for nephrotoxicity associated with cisplatin. Can J Hosp Pharm 70:99\u2013106. https:\/\/doi.org\/10.4212\/cjhp.v70i2.1641","journal-title":"Can J Hosp Pharm"},{"key":"6985_CR14","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1200\/JCO.2008.17.5257","volume":"27","author":"O Oberlin","year":"2009","unstructured":"Oberlin O, Fawaz O, Rey A et al (2009) Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol 27:5350\u20135355. https:\/\/doi.org\/10.1200\/JCO.2008.17.5257","journal-title":"J Clin Oncol"},{"issue":"12","key":"6985_CR15","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui C-H et al (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21:1471\u20131482. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"key":"6985_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/phar.1360","volume":"34","author":"BC Widemann","year":"2014","unstructured":"Widemann BC, Schwartz S, Jayaprakash N et al (2014) Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy 34:427\u2013439. https:\/\/doi.org\/10.1002\/phar.1360","journal-title":"Pharmacotherapy"},{"key":"6985_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115292","volume":"166","author":"F Moradbeygi","year":"2023","unstructured":"Moradbeygi F, Ghasemi Y, Farmani AR, Hemmati S (2023) Glucarpidase (carboxypeptidase G2): biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy. Biomed Pharmacother 166:115292. https:\/\/doi.org\/10.1016\/j.biopha.2023.115292","journal-title":"Biomed Pharmacother"},{"key":"6985_CR18","unstructured":"Voraxaze (glucarpidase) (2012) Prescribing information. US Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125327lbl.pdf. Accessed 09 Feb 2025"},{"key":"6985_CR19","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1158\/1055-9965.EPI-13-0036","volume":"22","author":"RL Mulder","year":"2013","unstructured":"Mulder RL, Knijnenburg SL, Geskus RB et al (2013) Glomerular function time trends in long-term survivors of childhood cancer: a longitudinal study. Cancer Epidemiol Biomarkers Prev 22:1736\u20131746. https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-0036","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"6985_CR20","first-page":"4151","volume":"10","author":"V Chiruvella","year":"2020","unstructured":"Chiruvella V, Annamaraju P, Guddati AK (2020) Management of nephrotoxicity of chemotherapy and targeted agents: 2020. Am J Cancer Res 10:4151\u20134164","journal-title":"Am J Cancer Res"},{"key":"6985_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174086","volume":"14","author":"M Bor\u00f3wka","year":"2022","unstructured":"Bor\u00f3wka M, \u0141\u0105cki-Zynzeling S, Nicze M et al (2022) Adverse renal effects of anticancer immunotherapy: a review. Cancers (Basel) 14:4086. https:\/\/doi.org\/10.3390\/cancers14174086","journal-title":"Cancers (Basel)"},{"key":"6985_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950923","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Ming Y, Fu R et al (2022) The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol 13:950923. https:\/\/doi.org\/10.3389\/fphar.2022.950923","journal-title":"Front Pharmacol"},{"key":"6985_CR23","doi-asserted-by":"publisher","first-page":"26886","DOI":"10.1038\/s41598-024-77720-z","volume":"14","author":"E Russo","year":"2024","unstructured":"Russo E, Gambella M, Raiola AM et al (2024) Acute kidney injury in hematological patients treated with CAR-T cells: risk factors, clinical presentation and impact on outcomes. Sci Rep 14:26886. https:\/\/doi.org\/10.1038\/s41598-024-77720-z","journal-title":"Sci Rep"},{"key":"6985_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","volume":"26","author":"V Gutgarts","year":"2020","unstructured":"Gutgarts V, Jain T, Zheng J et al (2020) Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery. Biol Blood Marrow Transplant 26:1071\u20131076. https:\/\/doi.org\/10.1016\/j.bbmt.2020.02.012","journal-title":"Biol Blood Marrow Transplant"},{"key":"6985_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40259-023-00599-1","volume":"37","author":"AO G\u00e9rard","year":"2023","unstructured":"G\u00e9rard AO, Merino D, Charbinat A et al (2023) Car-t cells and the kidney: insights from the WHO safety database. BioDrugs 37:521\u2013530. https:\/\/doi.org\/10.1007\/s40259-023-00599-1","journal-title":"BioDrugs"},{"key":"6985_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13014-021-01764-y","volume":"16","author":"R Klaus","year":"2021","unstructured":"Klaus R, Niyazi M, Lange-Sperandio B (2021) Radiation-induced kidney toxicity: molecular and cellular pathogenesis. Radiat Oncol 16:43. https:\/\/doi.org\/10.1186\/s13014-021-01764-y","journal-title":"Radiat Oncol"},{"key":"6985_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0270-9295(03)00093-7","volume":"23","author":"EP Cohen","year":"2003","unstructured":"Cohen EP, Robbins MEC (2003) Radiation nephropathy. Semin Nephrol 23:486\u2013499. https:\/\/doi.org\/10.1016\/S0270-9295(03)00093-7","journal-title":"Semin Nephrol"},{"key":"6985_CR28","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.kint.2022.05.029","volume":"102","author":"ECM Kooijmans","year":"2022","unstructured":"Kooijmans ECM, van der Pal HJH, Pluijm SMF et al (2022) The Dutch Childhood Cancer Survivor Study (DCCSS)-LATER 2 kidney analysis examined long-term glomerular dysfunction in childhood cancer survivors. Kidney Int 102:1136\u20131146. https:\/\/doi.org\/10.1016\/j.kint.2022.05.029","journal-title":"Kidney Int"},{"key":"6985_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3747\/co.26.5033","volume":"26","author":"A Bazinet","year":"2019","unstructured":"Bazinet A, Popradi G (2019) A general practitioner\u2019s guide to hematopoietic stem-cell transplantation. Curr Oncol 26:187\u2013191. https:\/\/doi.org\/10.3747\/co.26.5033","journal-title":"Curr Oncol"},{"key":"6985_CR30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/bjh.16557","volume":"190","author":"MS Cairo","year":"2020","unstructured":"Cairo MS, Cooke KR, Lazarus HM, Chao N (2020) Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation. Br J Haematol 190:822\u2013836. https:\/\/doi.org\/10.1111\/bjh.16557","journal-title":"Br J Haematol"},{"key":"6985_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0272-6386(89)80054-X","volume":"13","author":"RA Zager","year":"1989","unstructured":"Zager RA, O\u2019Quigley J, Zager BK et al (1989) Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 13:210\u2013216. https:\/\/doi.org\/10.1016\/S0272-6386(89)80054-X","journal-title":"Am J Kidney Dis"},{"key":"6985_CR32","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","volume":"56","author":"JA Young","year":"2021","unstructured":"Young JA, Pallas CR, Knovich MA (2021) Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transplant 56:1805\u20131817. https:\/\/doi.org\/10.1038\/s41409-021-01283-0","journal-title":"Bone Marrow Transplant"},{"key":"6985_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00133","volume":"7","author":"CC Dvorak","year":"2019","unstructured":"Dvorak CC, Higham C, Shimano KA (2019) Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management. Front Pediatr 7:133. https:\/\/doi.org\/10.3389\/fped.2019.00133","journal-title":"Front Pediatr"},{"key":"6985_CR34","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1055\/s-0039-1692721","volume":"119","author":"E Gavriilaki","year":"2019","unstructured":"Gavriilaki E, Chrysanthopoulou A, Sakellari I et al (2019) Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy. Thromb Haemost 119:1433\u20131440. https:\/\/doi.org\/10.1055\/s-0039-1692721","journal-title":"Thromb Haemost"},{"key":"6985_CR35","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","volume":"4","author":"S Jodele","year":"2020","unstructured":"Jodele S, Medvedovic M, Luebbering N et al (2020) Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv 4:1166\u20131177. https:\/\/doi.org\/10.1182\/bloodadvances.2020001515","journal-title":"Blood Adv"},{"key":"6985_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"ML Schoettler","year":"2023","unstructured":"Schoettler ML, Carreras E, Cho B et al (2023) Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther 29:151\u2013163. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.015","journal-title":"Transplant Cell Ther"},{"key":"6985_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","volume":"29","author":"S Jodele","year":"2015","unstructured":"Jodele S, Laskin BL, Dandoy CE et al (2015) A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 29:191\u2013204. https:\/\/doi.org\/10.1016\/j.blre.2014.11.001","journal-title":"Blood Rev"},{"key":"6985_CR38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/hematology.2024000545","volume":"2024","author":"A Li","year":"2024","unstructured":"Li A, Sartain SE (2024) Transplant-associated TMA: the conundrum of diagnosis and treatment. Hematology 2024:206\u2013213. https:\/\/doi.org\/10.1182\/hematology.2024000545","journal-title":"Hematology"},{"key":"6985_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12935","volume":"21","author":"R Raina","year":"2017","unstructured":"Raina R, Herrera N, Krishnappa V et al (2017) Hematopoietic stem cell transplantation and acute kidney injury in children: a comprehensive review. Pediatr Transplant 21:e12935. https:\/\/doi.org\/10.1111\/petr.12935","journal-title":"Pediatr Transplant"},{"key":"6985_CR40","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s00467-024-06290-z","volume":"39","author":"B Avc\u0131","year":"2024","unstructured":"Avc\u0131 B, Bilir \u00d6A, \u00d6zl\u00fc SG et al (2024) Acute kidney injury and risk factors in pediatric patients undergoing hematopoietic stem cell transplantation. Pediatr Nephrol 39:2199\u20132207. https:\/\/doi.org\/10.1007\/s00467-024-06290-z","journal-title":"Pediatr Nephrol"},{"key":"6985_CR41","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.kint.2021.05.030","volume":"100","author":"G Lugthart","year":"2021","unstructured":"Lugthart G, Jordans CCE, de Pagter APJ et al (2021) Chronic kidney disease ten years after pediatric allogeneic hematopoietic stem cell transplantation. Kidney Int 100:906\u2013914. https:\/\/doi.org\/10.1016\/j.kint.2021.05.030","journal-title":"Kidney Int"},{"key":"6985_CR42","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000045085","volume":"79","author":"EP Cohen","year":"1998","unstructured":"Cohen EP, Piering WF, Kabler-Babbitt C, Moulder JE (1998) End-stage renal disease (ESRD) after bone marrow transplantation: poor survival compared to other causes of ESRD. Nephron 79:408\u2013412. https:\/\/doi.org\/10.1159\/000045085","journal-title":"Nephron"},{"key":"6985_CR43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1399-3046.2004.00208.x","volume":"8","author":"SE Thomas","year":"2004","unstructured":"Thomas SE, Hutchinson RJ, DebRoy M, Magee JC (2004) Successful renal transplantation following prior bone marrow transplantation in pediatric patients. Pediatr Transplant 8:507\u2013512. https:\/\/doi.org\/10.1111\/j.1399-3046.2004.00208.x","journal-title":"Pediatr Transplant"},{"key":"6985_CR44","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s00467-020-04800-3","volume":"36","author":"A Nada","year":"2021","unstructured":"Nada A, Jetton JG (2021) Pediatric onco-nephrology: time to spread the word. Pediatr Nephrol 36:2227\u20132255. https:\/\/doi.org\/10.1007\/s00467-020-04800-3","journal-title":"Pediatr Nephrol"},{"key":"6985_CR45","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00467-021-05172-y","volume":"37","author":"A Nada","year":"2022","unstructured":"Nada A, Jetton JG (2022) Pediatric onco-nephrology: time to spread the word-Part II: long-term kidney outcomes in survivors of childhood malignancy and malignancy after kidney transplant. Pediatr Nephrol 37:1285\u20131300. https:\/\/doi.org\/10.1007\/s00467-021-05172-y","journal-title":"Pediatr Nephrol"},{"key":"6985_CR46","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/S1470-2045(19)30418-8","volume":"20","author":"AC Dietz","year":"2019","unstructured":"Dietz AC, Seidel K, Leisenring WM et al (2019) Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the childhood cancer survivor study. Lancet Oncol 20:1420\u20131431. https:\/\/doi.org\/10.1016\/S1470-2045(19)30418-8","journal-title":"Lancet Oncol"},{"key":"6985_CR47","unstructured":"Children\u2019s Oncology Group (2023) Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers (Version 6.0). https:\/\/www.survivorshipguidelines.org\/. Accessed 02 Feb 2025"},{"key":"6985_CR48","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ejca.2021.06.004","volume":"154","author":"RJ van Kalsbeek","year":"2021","unstructured":"van Kalsbeek RJ, van der Pal HJH, Kremer LCM et al (2021) European PanCareFollowUp recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer. Eur J Cancer 154:316\u2013328. https:\/\/doi.org\/10.1016\/j.ejca.2021.06.004","journal-title":"Eur J Cancer"},{"key":"6985_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpeds.2022.10.029","volume":"255","author":"W Hsiao","year":"2023","unstructured":"Hsiao W, Lapite A, Faig W (2023) Long-term kidney and cardiovascular complications in pediatric cancer survivors. J Pediatr 255:89-97.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2022.10.029","journal-title":"J Pediatr"},{"key":"6985_CR50","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1200\/JCO.22.01926","volume":"41","author":"NL Wu","year":"2023","unstructured":"Wu NL, Chen Y, Dieffenbach BV et al (2023) Development and validation of a prediction model for kidney failure in long-term survivors of childhood cancer. J Clin Oncol 41:2258\u20132268. https:\/\/doi.org\/10.1200\/JCO.22.01926","journal-title":"J Clin Oncol"},{"key":"6985_CR51","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.21037\/tp-23-422","volume":"12","author":"A B\u00f6kenkamp","year":"2023","unstructured":"B\u00f6kenkamp A, Kooijmans E (2023) Prediction of kidney failure in long-term survivors of childhood cancer\u2014an opportunity for intervention in follow-up programs. Transl Pediatr 12:1935\u20131940. https:\/\/doi.org\/10.21037\/tp-23-422","journal-title":"Transl Pediatr"},{"key":"6985_CR52","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/ajt.16318","volume":"21","author":"DP Al-Adra","year":"2021","unstructured":"Al-Adra DP, Hammel L, Roberts J et al (2021) Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement. Am J Transplant 21:460\u2013474. https:\/\/doi.org\/10.1111\/ajt.16318","journal-title":"Am J Transplant"},{"key":"6985_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy174","volume":"33","author":"M Cozzolino","year":"2018","unstructured":"Cozzolino M, Mangano M, Stucchi A (2018) Cardiovascular disease in dialysis patients. Nephrol Dial Transplant 33:iii28\u2013iii34. https:\/\/doi.org\/10.1093\/ndt\/gfy174","journal-title":"Nephrol Dial Transplant"},{"key":"6985_CR54","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1097\/TP.0000000000001659","volume":"101","author":"DO Dahle","year":"2017","unstructured":"Dahle DO, Grotmol T, Leivestad T et al (2017) Association between pretransplant cancer and survival in kidney transplant recipients. Transplantation 101:2599\u20132605. https:\/\/doi.org\/10.1097\/TP.0000000000001659","journal-title":"Transplantation"},{"key":"6985_CR55","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ajt.2022.11.006","volume":"23","author":"A Hart","year":"2023","unstructured":"Hart A, Pfeiffer RM, Morawski BM et al (2023) Mortality among solid organ transplant recipients with a pretransplant cancer diagnosis. Am J Transplant 23:257\u2013264. https:\/\/doi.org\/10.1016\/j.ajt.2022.11.006","journal-title":"Am J Transplant"},{"key":"6985_CR56","unstructured":"The Norwegian Renal Association (2015) Norwegian Transplantation Protocol kidney, pancreas, and islet cell transplantation. https:\/\/www.nephro.no\/foreningsnytt\/Tx-Protokoll-2015.pdf. Accessed 03 Sept 2025"},{"key":"6985_CR57","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1053\/j.ajkd.2020.11.017","volume":"77","author":"CM Puttarajappa","year":"2021","unstructured":"Puttarajappa CM, Schinstock CA, Wu CM et al (2021) KDOQI US commentary on the 2020 KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Am J Kidney Dis 77:833\u2013856. https:\/\/doi.org\/10.1053\/j.ajkd.2020.11.017","journal-title":"Am J Kidney Dis"},{"key":"6985_CR58","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/ajt.16324","volume":"21","author":"DP Al-Adra","year":"2021","unstructured":"Al-Adra DP, Hammel L, Roberts J et al (2021) Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement. Am J Transplant 21:475\u2013483. https:\/\/doi.org\/10.1111\/ajt.16324","journal-title":"Am J Transplant"},{"key":"6985_CR59","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.2215\/CJN.03630415","volume":"10","author":"S Ploos van Amstel","year":"2015","unstructured":"Ploos van Amstel S, Vogelzang JL, Starink MV et al (2015) Long-term risk of cancer in survivors of pediatric ESRD. Clin J Am Soc Nephrol 10:2198\u20132204. https:\/\/doi.org\/10.2215\/CJN.03630415","journal-title":"Clin J Am Soc Nephrol"},{"key":"6985_CR60","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jamcollsurg.2017.04.012","volume":"225","author":"OK Serrano","year":"2017","unstructured":"Serrano OK, Bangdiwala AS, Vock DM et al (2017) Post-transplant malignancy after pediatric kidney transplantation: retrospective analysis of incidence and risk factors in 884 patients receiving transplants between 1963 and 2015 at the University of Minnesota. J Am Coll Surg 225:181\u2013193. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2017.04.012","journal-title":"J Am Coll Surg"},{"key":"6985_CR61","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/ckj\/sfac013","volume":"15","author":"JD Fuhrmann","year":"2022","unstructured":"Fuhrmann JD, Valkova K, von Moos S et al (2022) Cancer among kidney transplant recipients >20 years after transplantation: post-transplant lymphoproliferative disorder remains the most common cancer type in the ultra long-term. Clin Kidney J 15:1152\u20131159. https:\/\/doi.org\/10.1093\/ckj\/sfac013","journal-title":"Clin Kidney J"},{"key":"6985_CR62","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ndt\/gfp497","volume":"25","author":"F Koukourgianni","year":"2010","unstructured":"Koukourgianni F, Harambat J, Ranchin B et al (2010) Malignancy incidence after renal transplantation in children: a 20-year single-centre experience. Nephrol Dial Transplant 25:611\u2013616. https:\/\/doi.org\/10.1093\/ndt\/gfp497","journal-title":"Nephrol Dial Transplant"},{"key":"6985_CR63","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1093\/jnci\/djaf106","volume":"117","author":"PC Nathan","year":"2025","unstructured":"Nathan PC, Lau C, Ng VL et al (2025) Outcomes after solid organ transplantation in survivors of childhood, adolescent, and young adult cancer: a population-based study. J Natl Cancer Inst 117:1809\u20131816. https:\/\/doi.org\/10.1093\/jnci\/djaf106","journal-title":"J Natl Cancer Inst"},{"key":"6985_CR64","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.transproceed.2015.11.020","volume":"48","author":"H-F Chiu","year":"2016","unstructured":"Chiu H-F, Chung M-C, Chung C-J et al (2016) Prognosis of kidney transplant recipients with pretransplantation malignancy: a nationwide population-based cohort study in Taiwan. Transplant Proc 48:918\u2013920. https:\/\/doi.org\/10.1016\/j.transproceed.2015.11.020","journal-title":"Transplant Proc"},{"key":"6985_CR65","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00467-020-04546-y","volume":"35","author":"K End\u00e9n","year":"2020","unstructured":"End\u00e9n K, Tainio J, Nikkil\u00e4 A et al (2020) Cancer morbidity and mortality after pediatric solid organ transplantation\u2014a nationwide register study. Pediatr Nephrol 35:1719\u20131728. https:\/\/doi.org\/10.1007\/s00467-020-04546-y","journal-title":"Pediatr Nephrol"},{"key":"6985_CR66","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.trre.2017.08.003","volume":"31","author":"SA Acuna","year":"2017","unstructured":"Acuna SA, Huang JW, Dossa F (2017) Cancer recurrence after solid organ transplantation: a systematic review and meta-analysis. Transplant Rev 31:240\u2013248. https:\/\/doi.org\/10.1016\/j.trre.2017.08.003","journal-title":"Transplant Rev"},{"key":"6985_CR67","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/jnci\/djp417","volume":"101","author":"K Wasilewski-Masker","year":"2009","unstructured":"Wasilewski-Masker K, Liu Q, Yasui Y et al (2009) Late recurrence in pediatric cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 101:1709\u20131720. https:\/\/doi.org\/10.1093\/jnci\/djp417","journal-title":"J Natl Cancer Inst"},{"key":"6985_CR68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","volume":"8","author":"Z Al-Mansour","year":"2013","unstructured":"Al-Mansour Z, Nelson BP, Evens AM (2013) Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep 8:173\u2013183. https:\/\/doi.org\/10.1007\/s11899-013-0162-5","journal-title":"Curr Hematol Malig Rep"},{"key":"6985_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/150835","volume":"2013","author":"J Morscio","year":"2013","unstructured":"Morscio J, Dierickx D, Tousseyn T (2013) Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol 2013:150835. https:\/\/doi.org\/10.1155\/2013\/150835","journal-title":"Clin Dev Immunol"},{"key":"6985_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020328","volume":"12","author":"A Fujimoto","year":"2020","unstructured":"Fujimoto A, Suzuki R (2020) Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation: pathogenesis, risk factors and clinical outcomes. Cancers (Basel) 12:328. https:\/\/doi.org\/10.3390\/cancers12020328","journal-title":"Cancers (Basel)"},{"key":"6985_CR71","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1097\/TP.0000000000004577","volume":"107","author":"L Zaffiri","year":"2023","unstructured":"Zaffiri L, Chambers ET (2023) Screening and management of PTLD. Transplantation 107:2316\u20132328. https:\/\/doi.org\/10.1097\/TP.0000000000004577","journal-title":"Transplantation"},{"key":"6985_CR72","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.athoracsur.2021.08.038","volume":"114","author":"K Giuliano","year":"2022","unstructured":"Giuliano K, Canner JK, Scully BB et al (2022) Epstein-barr virus predicts malignancy after pediatric heart transplant, induction therapy and tacrolimus don\u2019t. Ann Thorac Surg 114:1794\u20131802. https:\/\/doi.org\/10.1016\/j.athoracsur.2021.08.038","journal-title":"Ann Thorac Surg"},{"key":"6985_CR73","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","volume":"80","author":"S Caillard","year":"2005","unstructured":"Caillard S, Dharnidharka V, Agodoa L et al (2005) Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80:1233\u20131243. https:\/\/doi.org\/10.1097\/01.tp.0000179639.98338.39","journal-title":"Transplantation"},{"key":"6985_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.1087864","volume":"10","author":"R Fulchiero","year":"2022","unstructured":"Fulchiero R, Amaral S (2022) Post-transplant lymphoproliferative disease after pediatric kidney transplant. Front Pediatr 10:1087864. https:\/\/doi.org\/10.3389\/fped.2022.1087864","journal-title":"Front Pediatr"},{"key":"6985_CR75","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/ndt\/gfs476","volume":"28","author":"D Michonneau","year":"2013","unstructured":"Michonneau D, Suarez F, Lambert J et al (2013) Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. Nephrol Dial Transplant 28:471\u2013478. https:\/\/doi.org\/10.1093\/ndt\/gfs476","journal-title":"Nephrol Dial Transplant"},{"key":"6985_CR76","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.trre.2005.10.003","volume":"19","author":"MJ Hanaway","year":"2005","unstructured":"Hanaway MJ, Weber S, Buell JF et al (2005) Risk for recurrence and death from preexisting cancers after transplantation. Transplant Rev 19:151\u2013163. https:\/\/doi.org\/10.1016\/j.trre.2005.10.003","journal-title":"Transplant Rev"},{"issue":"1","key":"6985_CR77","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14697","volume":"28","author":"A Mandel","year":"2024","unstructured":"Mandel A, Robinson SG, Peticca B et al (2024) Pretransplant malignancy in pediatrics is not a risk factor for renal graft failure. Pediatr Transplant 28:e14697. https:\/\/doi.org\/10.1111\/petr.14697","journal-title":"Pediatr Transplant"},{"key":"6985_CR78","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ajt.2024.11.002","volume":"25","author":"H Kaijansinkko","year":"2025","unstructured":"Kaijansinkko H, Bonthuis M, Jahnukainen K et al (2025) Clinical outcomes of pediatric kidney replacement therapy after childhood cancer\u2014An ESPN\/ERA registry study. Am J Transplant 25:767\u2013779. https:\/\/doi.org\/10.1016\/j.ajt.2024.11.002","journal-title":"Am J Transplant"},{"key":"6985_CR79","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/TP.0000000000002378","volume":"103","author":"A Kitchlu","year":"2019","unstructured":"Kitchlu A, Dixon S, Dirk JS et al (2019) Elevated risk of cancer after solid organ transplant in childhood: a population-based cohort study. Transplantation 103:588\u2013596. https:\/\/doi.org\/10.1097\/TP.0000000000002378","journal-title":"Transplantation"},{"key":"6985_CR80","doi-asserted-by":"publisher","first-page":"F125","DOI":"10.1152\/ajprenal.00041.2003","volume":"288","author":"MH Hanigan","year":"2005","unstructured":"Hanigan MH, Deng M, Zhang L et al (2005) Stress response inhibits the nephrotoxicity of cisplatin. Am J Physiol Renal Physiol 288:F125\u2013F132. https:\/\/doi.org\/10.1152\/ajprenal.00041.2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"6985_CR81","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Bernard Tchounwou P (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364\u2013378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025","journal-title":"Eur J Pharmacol"},{"key":"6985_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106939","volume":"203","author":"EA Elmorsy","year":"2024","unstructured":"Elmorsy EA, Saber S, Hamad RS et al (2024) Advances in understanding cisplatin-induced toxicity: molecular mechanisms and protective strategies. Eur J Pharm Sci 203:106939. https:\/\/doi.org\/10.1016\/j.ejps.2024.106939","journal-title":"Eur J Pharm Sci"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06985-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06985-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06985-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:26:45Z","timestamp":1779442005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06985-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["6985"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06985-x","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no financial or non-financial interests to disclose that could be directly or indirectly related to the work submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements and declarations\u00a0"}}]}}